Simon Thomas

This inventor holds 29 USPTO granted patents and 38 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: Autolus Limited, Ucl Business Plc. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Simon Thomas. Retrieved from https://idiyas.com/inventor/simon-thomas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 38)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 10 (Patent Applications = 48)

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 52(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptor

Cytolytic Immune Cell

CD19

CD22

BCMA

T Cell

NK Cell

Antigen Binding Domain

Cytokine Receptor

Polypeptide

Cancer Treatment

Transmembrane Protein

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516119 - ANTI TRBC1 ANTIGEN BINDING DOMAINS (2026-01-06),

2. 12492410 - Engineered Cytolytic Immunecell (2025-12-09),

3. 12454578 - Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors (2025-10-28),

4. 12398194 - Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface (2025-08-26),

5. 12325733 - Binding domain (2025-06-10),

6. 12241068 - CD79-specific chimeric antigen receptor (2025-03-04),

7. 12234295 - Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof (2025-02-25),

8. 12187769 - Cell (2025-01-07),

9. 12049510 - Chimeric antigen receptor (2024-07-30),

10. 11963981 - Chimeric antigen receptor (2024-04-23),

11. 11879016 - Chimeric antigen receptor (2024-01-23),

12. 11701386 - Cell (2023-07-18),

13. 11648274 - Polypeptide (2023-05-16),

14. 11590170 - Chimeric antigen receptor (2023-02-28),

15. 11479614 - Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors (2022-10-25),

Title: Simon Thomas: Pioneering Innovator Inspiring Future Generations

Introduction:

Simon Thomas, a visionary inventor based in London, GB, is renowned for his unwavering passion for creating a more sustainable and technologically advanced future. With 21 patents to his name, Simon has solidified his legacy as a true trailblazer in the world of innovation, continuously pushing boundaries and sparking inspiration among budding inventors.

Latest Patents:

Among Simon's latest patents is the groundbreaking 'Chimeric Antigen Receptor,' a revolutionary technology designed to target antigens associated with diseases. This cutting-edge invention holds tremendous promise in the treatment of various conditions, showcasing Simon's commitment to advancing healthcare through innovation.

Career Highlights:

Simon's impressive career includes impactful stints at leading companies such as Autolus Limited and UCL Business PLC, where he honed his skills and spearheaded numerous groundbreaking projects. His relentless pursuit of innovation and excellence has set him apart as a pioneering force in the industry.

Collaborations:

Throughout his career, Simon has collaborated with esteemed professionals such as Martin Pulé and Shaun Cordoba, pooling together their expertise to drive forward groundbreaking initiatives. These collaborations have not only resulted in significant technological advancements but also fostered a culture of innovation and collaboration in the industry.

Conclusion:

Simon Thomas continues to inspire the next generation of inventors with his trailblazing spirit and dedication to creating a better world through innovation. His remarkable contributions to the field of technology and healthcare stand as a testament to his enduring legacy as a visionary inventor shaping the future of innovation.

Profile summary based on public USPTO records.